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Metformin is a commonly prescribed type II diabetes medication that exhibits promising anticancer effects. Recently, these
effects were found to be associated, at least in part, with a modulation of microRNA expression. However, the mechanisms by
which single modulated microRNAs mediate the anticancer effects of metformin are not entirely clear and knowledge of such a
process could be vital to maximize the potential therapeutic beneﬁts of this safe and well-tolerated therapy. Our analysis here
revealed that the expression of miR-21-5p was downregulated in multiple breast cancer cell lines treated with pharmacologically
relevant doses of metformin. Interestingly, the inhibition of miR-21-5p following metformin treatment was also observed in mouse
breast cancer xenografts and in sera from 96 breast cancer patients. This modulation occurred at the levels of both pri-miR-21
and pre-miR-21, suggesting transcriptional modulation. Antagomir-mediated ablation of miR-21-5p phenocopied the effects of
metformin on both the clonogenicity and migration of the treated cells, while ectopic expression of miR-21-5p had the opposite
effect. Mechanistically, this reduction in miR-21-5p enhanced the expression of critical upstream activators of the AMP-
activated protein kinase, calcium-binding protein 39-like and Sestrin-1, leading to AMP-activated protein kinase activation and
inhibition of mammalian target of rapamycin signaling. Importantly, these effects of metformin were synergistic with those of
everolimus, a clinically relevant mammalian target of rapamycin inhibitor, and were independent of the phosphatase and tensin
homolog status. This highlights the potential relevance of metformin in combinatorial settings for the treatment of breast cancer.
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Introduction
The ability to suppress hepatic gluconeogenesis and
reduce blood glucose levels, together with its safe
proﬁle have made the dimethyl-biguanide metformin a
worldwide prescribed agent for type II diabetes
patients[1]. Recent epidemiological studies supported a
new therapeutic role for metformin toward the
prevention and treatment of cancer. In detail, type II
diabetes patients treated with metformin showed an
important reduction in cancer risk compared with
those treated with other hypoglycemic therapies[2].
Chronic treatment with metformin in diabetic
patients was associated with a reduction, in several
types of cancer, of the incidence compared with other
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antidiabetic agents[3], ﬁndings which led to the
initiation of many clinical trials testing the preventive
effects of the drug in numerous cancers. Given its
excellent safety proﬁle, metformin has also been used to
enhance the effects of chemotherapies[4, 5]. Further,
mammalian target of rapamycin (mTOR) inhibition,
mediated by metformin, sensitized breast cancer
cell lines and thyroid cancer cells to cytotoxic effect of
everolimus and vemurafenib, respectively[6, 7].
Despite these promising clinical data, the mechanisms
by which metformin elicits antiproliferative effects
alone or in combination with other agents are not fully
understood but vital to understand in order to guide
clinical development. The AMP-activated-protein-
kinase (AMPK) is a main mediator of the
metformin-anticancer activities. It is activated upon
phosphorylation of Thr172 within the catalytic
alpha-subunit by the LKB1–STRAD–CAB39L
(CAB39L is also known as MO25β) complex[8–10].
The calcium-binding protein 39 (Cab39 or MO25)
exists as two isoforms, encoded by the closely related
genes MO25α (CAB39) and MO25β (CAB39L). It is a
scaffold protein that binds and stabilizes the LKB1
activation loop in a conformation required for
phosphorylation of substrates[8]. In particular, its
presence enhances the regulatory effect of the
pseudokinases, STE20-like kinase family, STRADα
and STRADβ, on the activity of LKB1. AMPK is
further activated through Sestrin-1 (SESN1)[11], this
latter being a critical factor at the interface between
metabolism and cancer[12, 13]. Importantly, in cells
lacking LKB1 or AMPK cell growth is uncontrolled
[14], as being at least partially fuelled by a glycolytic
switch that maximizes macromolecule synthesis.
Those effects were counteracted by metformin treat-
ment[15, 16]. Moreover, AMPK activation inhibited
the mTOR pathways, which is constitutively activated
in a broad spectrum of tumors[17], thus representing an
appealing target for cancer treatment. As a
consequence, mTOR was no longer able to promote
protein synthesis pathways through the activation
of S6 kinase (S6K) and translation initiation factor 4E
binding protein 1 (4EBP1). This resulted in an
inhibition of the mTOR oncogenic signaling, which
mainly required S6K and active protein synthesis[18].
Surprisingly, despite the well-known actions of
metformin toward AMPK, the mechanisms by which
metformin elicits activation of the kinase in tumors
are still not fully understood. Notably, in contrast
to the liver which has high concentrations of
metformin that disrupt oxidative phosphorylation,
the tumor concentrations of metformin are much
lower. However, such doses were found to
be sufﬁcient to activate AMPK in tumor
xenografts[19–21].
We recently showed that metformin-induced
anticancer effects correlated with decreased levels of
multiple microRNAs (miRNA), through an E2F1/3-
dependent modulation of the DICER processing
enzyme. This elicited metabolic reprogramming in vivo
and in vitro and correlated with metformin’s anticancer
effects[22]. miRNAs are important modulators of the
cancer phenotype. It has been demonstrated that an
aberrant expression of a single miRNA can, alone,
induce and sustain cancer, while its silencing
could induce reversion of the tumor[23–25]. Within
this line, miR-21-5p represents a paradigmatic
example. Its inactivation has been found to induce a
complete tumor regression, thus demonstrating that
cancer can be addicted to a single oncomiR[26].
miR-21-5p was found, also, to be overexpressed in
most of the tumor types examined so far, including
neuroblastoma, glioblastoma, colorectal, lung,
breast, pancreas, head and neck, gastric cancer,
leukemia and lymphoma[27–32]. Moreover, in a
large-scale analysis of 540 human samples representing
6 different tumor histotypes, miR-21 was the only
upregulated miRNA common to all the tumor
specimens[33]. Further, its circulating levels in serum
or plasma were found to be diagnostic and prognostic
for detecting and staging breast[34], pancreatic[35] and
colorectal cancer[36].
In the current study, we have discovered that met-
formin induced a decrease in the oncogenic miR-21-5p
in cultured human breast cancer cells in vitro, in mouse
xenografts and in sera of breast cancer patients.
Decreased miR-21-5p released the expression of two,
yet undiscovered miR-21-5p targets, SESN1 and
CAB39L, leading to the activation of AMPK. This
caused inhibition of mTOR following the activation of
the AMPK cascade and strictly correlated with a
reduced clonogenicity, migration and invasion of
multiple breast cancer cell lines. Changes in the
miR-21-5p levels and of the stoichiometry of the
CAB39L-LKB1 complexes were important for met-
formin’s effects in both PTENwt and PTENdel cell
lines. Finally, we explored the possibility of combining
metformin with everolimus to enhance the activity of
the latter, which was weaker in breast cancer
cell lines harboring a PTENwt allele. Thus here
we further characterized the complex yet
promising action of metformin and indicated a
potential, translationally relevant combination
therapy.
Metformin in antitumoral activities
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Results
Metformin modulates the levels of miR-21-5p
We have shown that metformin anticancer effects
include and require a widespread modulation of
miRNAs[22]. Here we deepened such observation
and focused on miR-21-5p, among the miRNAs pro-
minently modulated in the SUM159PT triple-negative
breast cancer cells, treated with pharmacologically
relevant doses of metformin (0.5mM) (Figure 1a and
Supplementary Figure S1a)[21, 37]. By using
quantitative PCR (qPCR), we speciﬁcally evaluated
the levels of the miR-21-5p precursors (pre-miR-21-5p
and pri-miR-21-5p) in the treated SUM159PT cells
(Figure 1a). This revealed that both the miR-21-5p
species were steadily downregulated, as compared with
the control cells (Po0.05), thus suggesting that
modulation of the miR-21-5p levels by metformin
may occur transcriptionally. This phenomenon
was common to three additional breast cancer cell
lines (MCF-7, BT-474, BT-549) (Supplementary
Figure S1b). Next, we assessed whether the modula-
tion of miR-21-5p by metformin may take place in
more clinically relevant experimental systems
(Figure 1b and c). First, we evaluated the miR-21-5p
levels in RNA extracted from pooled SUM159PT
tumors of mice treated with vehicle or metformin
(16mg kg− 1, bi-weekly), for 10 weeks, after the average
starting tumor volume was 0.2 cm3. This showed that
the levels of miR-21-5p signiﬁcantly dropped in the
metformin-treated mice, as compared with the
vehicle-treated ones (Figure 1b). To validate these
experimental data, we analyzed the levels of miR-21-5p
in the sera of patients (n = 96) with history of breast
cancer, collected before and after 3 months of daily
treatment with metformin (500mg day− 1)[38]. We
observed that serum levels of the miR-21-5p were
decreased in most of the patients after a 3-month
treatment (Figure 1c). Additionally, we found that
transfection of SUM159PT and of three more breast
cancer cell lines (MCF-7, BT-474, BT-549) with a
miR-21-5p mimic or inhibitor strongly recapitulated
the effect of metformin treatment on both the
clonogenicity and migration of the treated cells
(Supplementary Figure S1f–i). Thus downregulation
of miR-21-5p by metformin happened in vitro and
in vivo and affected clonogenicity and migration of four
independent breast cancer cell lines. Intriguingly, in
silico analysis of the miR-21-5p promoter revealed the
presence of three E2F-binding sites, respectively, at
− 4530/− 4515 (ﬁrst site), − 2834/− 2814 (second site)
and − 2216/− 2204 (third side) base pairs from
translational starting sites (ATG) (Figure 1e). E2F3
was capable of transcriptional repression[39] and was
already shown to be a target of metformin in a similar
experimental context[22, 40]. Thus we evaluated
whether metformin treatment may cause variations in
the occupancy of the miR-21-5p promoter by E2F3.
First, we veriﬁed that, in vitro, transfection of
increasing doses of E2F3 strongly reduced the activity
of a miR-21-5p-promoter-LUC vector containing the
proximal E2F3-binding site (Figure 1d). Conversely,
the repressive effect of E2F3 was lost when its binding
consensus sequence was mutated, ensuring speciﬁcity
of our observation (Figure 1d). Next, chromatin
immunoprecipitation revealed increased binding of
E2F3 at all the three sites of the miR-21-5p promoter
analyzed (Figure 1e and Supplementary Figure S1d
and e). This correlated with decreased signal, in the
same regions, for the hyper-acetylated Histone H4,
which reached statistical signiﬁcance in two out of the
three regions (Figure 1e and Supplementary
Figure S1d and e). The presence of hyper-acetylated
Histone H4 is generally considered an indicator of
transcriptionally active chromatin[41]. Thus its
decrease, concomitant with increased binding of E2F3,
indicated transcriptional repression and correlated
with decreased activity of the miR-21-5p promoter.
Moreover, qPCR showed an increase of the E2F3
transcript in time after metformin treatment
(Figure 1f), which paired the increased presence of this
factor on the miR-21-5p promoter (Figure 1e). Finally,
small interfering RNA (siRNA)-mediated silencing of
E2F3 impaired the ability of metformin at reducing the
colony-forming ability of treated SUM159PT cells
(Figure 1g). This caused the levels of miRNA 21-5p
being left unstimulated in the presence of metformin
(Supplementary Figure S1c).
CAB39L and SESN1 are modulated by metformin-
miR-21-5p
To study the mechanistic details of the metformin
effect on miR-21-5p, we performed an extensive
in silico analysis to search for mRNAs that contained
miR-21-5p binding sites in their 3′ untranslated region
(UTR) and whose levels anticorrelated with those of
the miR-21-5p. We found that both CAB39L and
SESN1 mRNAs fulﬁlled those two criteria and this
happened similarly in gastric cancer, head and neck
and breast cancer cohorts of patients (Table 1). First,
RNA-Seq of metformin-treated SUM159PT cells
conﬁrmed that SESN1 and CAB39L transcripts were,
indeed, signiﬁcantly upregulated when compared with
control-treated cells (Supplementary Figure S2a).
Claudio Pulito et al.
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We conﬁrmed such a similar modulation in three
additional breast cancer cell lines (MCF-7, BT-474,
BT-549) by qPCR (Figure 2a and b). Finally,
increased mRNA levels paired with increased protein
levels of both SESN1 and CAB39L in the treated
SUM159PT cells (Figure 2c). We also found increased
CAB39L expression in sections of tumors excised from
SUM159PT xenografted mice treated with metformin
(Supplementary Figure S2b). On a similar note,
Kaplan–Meier analysis showed that breast cancer
patients with higher expression of both SESN1 and
CAB39L exhibited better survival (Supplementary
Figure S2c). Altogether, these data suggested a
possible clinically relevant effect of metformin on the
two miR-21-5p targets. To validate these ﬁndings, we
studied the effect of exogenously added miR-21-5p
inhibitor on the levels of CAB39L and SESN1
(Figure 2d–f). We found increased mRNA and
protein levels of CAB39L and SESN1 (Figure 2e–g) in
cells transfected with 0.5–1 nM of miR-21-5p inhibitor,
the latter concentrations of antagonist being those that
more closely mimicked the effect of metformin on the
endogenous mRNAs. This correlated with a signiﬁcant
reduction in the ability of the interfered cells at forming
colonies and to migrate (Figure 2h and i). Conversely,
we found that a miR-21-5p mimic transfected in
Metformin in antitumoral activities
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SUM159PT cells caused a decrease of both SESN1 and
CAB39L endogenous mRNAs (Figure 2j) and reduced,
dose-dependently, both SESN1 3′-UTR- and CAB39L
3′-UTR-driven luciferase activity (Figure 2k and l).
Such effect was not observed when the miR-21-5p seed
sequence was mutated, ensuring the speciﬁcity of our
observation (Figure 2k and l). Thus the miR-21-5p
could directly modulate the SESN1 and CAB39L
levels, thereby strictly mimicking the effect of
metformin on those mRNAs.
Biochemical effects of metformin-induced increase of
CAB39L and SESN1
Metformin is an AMPK activator and we assessed
whether the effect of altering CAB39L and SESN1
levels in metformin-treated cells would impinge on the
AMPK signaling (Figure 3a and b). Staining of
whole-cell lysates obtained from vehicle- and
metformin-treated cells revealed that metformin-
induced levels of CAB39L and SESN1 in
SUM159PT cells tightly matched the activation of
AMPK and the downregulation of the mTOR signal-
ing, as assessed by reduced (phospho-ser2448)-mTOR,
(phospho-ser235/236)-S6 and (phospho-thr37/46)-4-EBP1
(Figure 3a and b, upper and lower panels,
respectively). siRNA-mediated downregulation of
CAB39L and SESN1 exerted opposite effects to those
of metformin on the phosphorylation of the mentioned
signaling molecules (Figure 3a and b, upper and
lower panels, respectively). To further characterize,
mechanistically, this signaling, we found that depletion
of either CAB39L or SESN1 impinged on the
AMPK activation and on the mTOR inhibition
triggered by metformin, which were reduced and
increased, respectively, in transfected HEK-293 cells
(Supplementary Figure S3a and b). On the contrary,
cells transfected with both the coding sequence of
CAB39L and SESN1 showed higher levels of
phospho-AMPK on residue thr172 and a signiﬁcant
downregulation of the phospho-mTOR on the residue
ser2448 protein levels, as compared with their control
(Supplementary Figure S3c). Further, we found that
exogenous increase of the miR-21-5p could counteract
the effects of metformin, thus causing reduced
AMPK activation and increased phospho-mTOR
signal, as compared with the metformin-treated,
control-transfected cells (Supplementary Figure S3d,
upper and lower panels, respectively). On the other
hand, the same cells transfected with a miR-21-5p
agonist, in the presence of SESN1 and CAB39L
overexpression and without metformin treatment,
exhibited AMPK activation and mTOR inhibition
(Supplementary Figure S3d). Altogether, these
experiments revealed a rather complex interplay
between miR-21-5p and its two targets in metformin-
treated breast cancer cells.
Mechanistically, CAB39L is a scaffold protein that
binds to LKB1, thereby favoring the downstream
activation of AMPK[42]. Thus we assessed
whether metformin treatment enhanced the formation
of a LKB1/CAB39L protein complex. Reciprocal
coprecipitation experiments revealed that the LKB1/
CAB39L complex was more evident upon metformin
treatment, at least partially due to the increased of
Figure 1 Metformin downregulated the miR-21-5p expression. (a) Quantitative PCR. Expression of the pri- and pre-miR-21-5p in
SUM159PT cells treated with metformin (0.5 mM) for 24 h. Bars indicate the average of three independent experiments. Statistics (t-test):
Po0.05. (b, c) Modulation of miR-21-5p happened in vivo. (b) Relative levels of miR-21-5p (log2) expression in pooled SUM159PT
tumors treated intraperitoneally with vehicle (n = 4) or metformin (n = 4) (16 mg kg− 1, bi-weekly, for 10 weeks) when the average starting
tumor volume was 0.2 cm3. Statistics (t-test): Po0.05. (c) Scatter plot indicating the miR-21-5p fold changes (log2) in the sera of women
(n = 96) with established breast cancer collected before and after 3 months of daily treatment with metformin (500 mg day− 1). Each circle
indicates a patient with decreased (blue ones) or increased (red ones) levels of miR-21-5p as compared with the pretreatment levels.
Statistics: (Wilcoxon sign-rank test, matched samples) Po0.001. (d) Luciferase assay. HEK-293 cells co-transfected with the wild-type
or mutated miR-21-5p promoter/LUC reporter construct and with different doses of E2F3. Histograms show the normalized luciferase
values from three independent experiments. Statistics (t-test): Po0.05. (e) E2F3 binding to the miR-21-5p promoter mediated the effect
of metformin. Upper panel. Predicted E2F-binding sites in the miR-21-5p promoter. Horizontal bars indicate the three different
E2F-binding sites ampliﬁed in the chromatin immunoprecipitation experiment. Lower panel. Histograms showing the ampliﬁcation of the
E2F-binding sites in the chromatin precipitated with anti-E2F3 and anti-acetylated Histone H4 (Acetyl-H4), from vehicle and
metformin-treated (0.5 mM, 24 h) SUM159PT cells. Statistics (t-test): Po0.05. Please see additional data in Supplementary Figures
S1d and e (f) Metformin induced E2F3 transcriptional expression. Quantitative PCR. Relative expression of E2F3 in SUM159PT cells
treated with metformin (0.5 mM) for different times (0–720 min). Statistics (t-test): Po0.05 over untreated cell (dashed line). (g) Altering
the levels of E2F3 impaired the metformin effect on the SUM159PT clonogenic ability. Histograms showing the average percentage of
colonies formed by SUM159PT cells transfected with two different E2F3 siRNAs (or scrambled control) and treated with vehicle or
metformin (0.5 mM, 24 h) before seeding at clonal density. Statistics (t-test): Po0.05 *Signiﬁcant versus vehicle, **Signiﬁcant versus
control transfected cells treated with metformin.
Claudio Pulito et al.
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CAB39L levels (Figure 3c, left and right, respectively).
This correlated with the observed higher phosphor-
ylation of AMPK (Figure 3a and b). Finally, we
performed an LKB1-immune kinase assay and found
that metformin increased LKB1 kinase activity as
assessed by using a speciﬁc substrate peptide,
(Figure 3d). In line with this, we found that
downregulation of LKB1 by siRNA impaired the effect
of metformin on the clonogenicity of the transfected
cells (Supplementary Figure S3e).
Modulation of CAB39L and SESN1 impinged on
clonogenicity and invasiveness of breast cancer cells
We evaluated the biological consequences of met-
formin–miR-21-5p modulation of CAB39L and
SESN1 by means of clonogenic and migration assays
(Figure 4g–h and Supplementary Figure S4a–f).
Metformin treatment reduced the clonogenicity of
SUM159PT and that of the BT-474 and MCF-7 cells
(Figure 4a–c) and affected their migration as well
(Figure 4d–f, Supplementary Figure S4a and b).
This occurred similarly for metformin-treated BT-549
cells (Supplementary Figure S4c and d). The over-
expression of either CAB39L or SESN1 mimicked the
effect of metformin, while the depletion of CAB39L or
SESN1 increased both clonogenicity and migration of
all the breast cancer cell lines tested (Figure 4a–f,
Supplementary Figure S4a–d). This suggested that the
anticancer effect of metformin could at least partially
be mediated by these two novel miR-21-5p targets. On
the other hand, downregulation of either SESN1 or
CAB39L impaired, signiﬁcantly (Po0.05), the ability
of metformin to affect colony number and migration
(Figure 4g and h). These data suggest that CAB39L or
SESN1 depletion counteracted the metformin
antitumorigenic effects. In line with these observations,
we also found that, in SUM159PT transfected with a
miR-21-5p agonist, the effect of metformin was
attenuated, again in terms of colony-forming assay and
migration assays (Supplementary Figure S4e and f).
Finally, we evaluated the effect of overexpressing
miR-21-5p, CAB39L and SESN1 in SUM159PT. The
triple-transfected cells were signiﬁcantly less able at
forming colonies and to migrate when compared with
the untreated ones and their behavior was similar to the
metformin-treated ones (Supplementary Figure S4e
and f). It is worthy to note that both CAB39L and
SESN1 constructs do not have 3′-UTR, and
consequently miR-21-5p could not affect their
translation. Thus CAB39L and SESN1 overexpression
mimicked metformin effects.T
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Phosphatase and tensin homolog (PTEN) was not
involved in the metformin-mediated anticancer effect
The tumor-suppressor PTEN is a well-known target
of the miR-21-5p[43], and thus we aimed at addressing
whether modulation of PTEN may inﬂuence our
conclusion in this experimental system. First, we found
that metformin treatment reduced colony formation
and migration of the PTEN-devoid BT-549 cells
(Figure 5a and b, respectively). However, as being a
long-grown cell line, the BT-549 cells may harbor
additional genetic lesions, in addition to PTEN
deletion, ultimately inﬂuencing the interpretation of
Claudio Pulito et al.
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the results. Thus we evaluated the effect of metformin
on matched isogenic HCT116 cells, virtually differing
each other only for the deletion of the PTEN gene.
This revealed that metformin treatment affected
similarly both the clonogenicity and migration of the
isogenic colon carcinoma cells in a dose-dependent
way (Figure 5c and d and e and f, respectively). Thus
metformin effect may appear to be independent of the
PTEN status.
Metformin synergized with the mTOR inhibitor
everolimus
Everolimus is a promising mTOR inhibitor shown
to be effective in patients harboring hyperactive
phosphoinositide-3 kinase pathway while not
modifying the progression-free survival of patients
harboring ‘normal’ phosphoinositide-3 kinase pathway
activation in epidermal growth factor receptor
2-positive tumors[44]. As metformin treatment showed
similar potency on both PTEN-proﬁcient and -deﬁcient
cells, we assessed whether the anticancer activity of
everolimus could be potentiated in PTENwt cells by
the concomitant treatment with metformin. Regarding
this hypothesis, we explored whether combining
everolimus with metformin would exert synergistic
effects. We found that metformin enhanced
everolimus-induced killing of the PTENwt
SUM159PT cells, as assessed by label-free viability
assays (Figure 6a), combination index analysis of 72 h
viability test (Figure 6b) and by clonogenic assay
(Figure 6c). A similar effect was observed when
the everolimus treatment was coupled with miR-21-5p
antagonists; conversely, co-treatment with the
miR-21-5p mimic counteracted the everolimus-induced
cell killing of SUMPT159 cells (Supplementary Figure
S5a and b). This was evident when comparing the 50%
cytotoxic concentration (CC50) of the double-treated
cells (Table 2). Biochemically, concomitant treatment
with metformin and everolimus exhibited additive
effects on the mTOR downstream effectors, especially
with regard to inhibiting the phosphorylation
of 4-EBP1 at thr37/46 and of S6 at Ser235/236 (Figure 6d).
Again, treatment of the SUM159PT cells with the
miR-21-5p agonist effectively counteracted those
biochemical effects (Supplementary Figure S5c), in line
with the previous observations. As CAB39L and
SESN1 are the targets of metformin, we tested whether
manipulating their levels could inﬂuence the response
to everolimus. RNAi-mediated depletion of either
CAB39L or SESN1 rendered SUM159PT cells more
resistant to everolimus treatment, while ectopic
expression of either CAB39L or SESN1 (this latter
condition mimicking metformin treatment) increased
cell death in response to the drug, with signiﬁcant
changes in the CC50 of the treated cells (Figure 6e and
Table 2). Next we evaluated the effect of the
combination treatment (metformin plus everolimus) on
the matched PTEN-proﬁcient and -deﬁcient HCT116
cells (Figure 6f and g). This showed that the
co-administration of metformin potentiated the effect
of everolimus, which was signiﬁcantly less potent
toward PTENwt HCT116 cells when used alone
(Figure 6f). We also evaluated the migration of the
matched HCT116 cells co-treated with everolimus and
metformin (Figure 6g). Even in this case, we observed
synergy between the two drugs; however, this was less
evident in the PTENdel HCT116 cells (Figure 6g),
with both compounds less capable of inhibiting the
migration. Altogether these ﬁndings indicate that
downregulation of miR-21-5p expression by metfor-
min, followed by release of CAB39L and SESN1,
contributed to attenuating the mTOR aberrant activity
and rendering breast cancer cells more prone to cell
death induced by a clinically relevant mTOR inhibitor.
Figure 2 Calcium-binding protein 39-like (CAB39L) and Sestrin-1 (SESN1) are targets of metformin-miR-21-5p. (a, b) Quantitative PCR.
Histograms showing the relative levels of CAB39L (a) and SESN1 (b) mRNAs in SUM159PT, BT-474, MCF-7 and BT-549 cells, treated
with vehicle or metformin (0.5 mM) for 24 h. Statistics (t-test): Po0.05. (c) Representative western blotting with anti-CAB39L or SESN1
antibodies of whole-cell lysates from SUM159PT cells treated with vehicle or metformin (0.5 mM) for 24 h. Actin staining was used as a
loading control. (d–i) Modulation of CAB39L and SESN1 by metformin required miR-21-5p. (d–f) Quantitative PCR. Histograms showing
the relative levels of miR-21-5p (d), CAB39L (e) and SESN1 (f) mRNAs in SUM159PT transfected with different doses of miR-21-5p
inhibitor. Statistics (t-test): Po0.05. (g) Representative western blotting of whole-cell lysates from SUM159PT cells treated as from panel
(d–f), stained with the indicated antibodies. Actin staining was used as a loading control. (h, i) Colony-forming assay (h) and invasion
assay (i). Histograms showing average colony counts (h) or the number of migrated cells (i) of SUM159PT cells treated as from panel (g).
Statistics (t-test): Po0.05. (j) Quantitative PCR. mRNA levels of SESN1 or CAB39L in SUM159PT cells expressing either a control
vector or a miR-21-5p mimic vector. Bars indicate the average of three independent experiments. Statistics (t-test): Po0.05. (k, l) Dual
luciferase assay. SUM159PT cells co-transfected with the wild-type or mutated CAB39L (k) or SESN1 (l) 3′-untranslated region
luciferase reporter and, subsequently, with either a scrambled- or a speciﬁc miR-21-5p agonist. Histograms show the normalized
luciferase values from three independent experiments. Statistics (t-test): Po0.05.
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Thus concomitant metformin and everolimus treat-
ment may be exploited therapeutically.
Discussion
The biguanide metformin is the most widely used
drug for treatment of type II diabetes. The primary
systemic effect of metformin is the lowering of blood
glucose levels achieved through reduced hepatic
gluconeogenesis and increased glucose uptake in the
skeletal muscles[45]. Metformin treatment leads to
activation of AMPK in vitro and in vivo [46–48].
Epidemiological studies have demonstrated that
chronical metformin treatment affects insurgence and
Claudio Pulito et al.
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mitigates the progression of several tumors. This has
generated a plethora of reports addressing the potential
anticancer mechanisms of the drug and the
intracellular signaling it elicits, mainly downstream of
AMPK activation; however, it should be noted that the
growth-suppressive properties of metformin have
ancient roots and that AMPK is not always required
for the antiproliferative effects of metformin in cancer
tissues[49]. In line with this, the anticancer effect of
metformin does not appear only to be due to the
control of glucose levels, as equally effective glucose-
lowering-agents did not show relevant anticancer
activity. Additionally, to date, the molecular
mechanisms by which metformin leads to AMPK
activation are not entirely understood. We and others
have shown that metformin metabolic action resulted
in a direct and broad modulation of several miRNAs
that correlated with anticancer effects in vitro and
in vivo. Starting from this observation, we focused here
on the miR-21-5p, which we showed to be reduced by
metformin in breast cancer cell lines, xenografted
tumor tissues and in sera of metformin-treated breast
cancer patients. We provided evidence that metformin
modulates AMPK/mTOR signaling through
miR-21-5p-dependent regulation of the scaffold
proteins CAB39L and SESN1 (Figure 7). This hap-
pened, partially, through a metformin-dependent
increase in the stoichiometry of the CAB39L–LKB1
complex. Interestingly, these effects were mimicked
either by the overexpression of the targets (CAB39L
and SESN1) or by downregulating miR-21-5p.
Then we further characterized, for the ﬁrst time ever,
the speciﬁc functional interaction between metformin,
miR-21-5p and two effector targets, adding novelty
to our understanding of the metabolic-anticancer
properties of this promising compound. The involve-
ment of CAB39L in mediating the activation of
AMPK is already described[50]. With regard to
SESN1, it is of note that this protein is a p53 target
gene and is involved in linking DNA damage-induced
p53 activation to the mTOR signaling pathway[11]. In
this work, we showed upregulation of SESN1 in both
p53wt (MCF-7) and p53mut (BT-474; BT-549) cells
and in cells expressing undetectable p53wt
(SUM159PT)[51]. This raises the interesting possibility
that metformin-induced increase of SESN1 may be at
least partially p53 independent and thus metformin
treatment may be exploited in p53-null tumors. In line
with this, Buzzai et al. [52] also described a selectivity
of metformin treatment toward p53− /− tumor cell
growth. Of course, downregulation of the miR-21-5p
cannot be the only anticancer mechanism of metfor-
min. We have previously shown that upregulation of
miR-33a and downregulation of c-MYC was relevant
to metformin action in a similar experimental system
[22]. In our experimental system, we did not observe
changes in miR-33a levels upon downregulation of
miR-21-5p, thus suggesting that the two mechanisms
ignited by metformin may act independently. In line
with this, we found that downregulation of miR-21-5p
mainly took place at the transcriptional levels follow-
ing increased occupancy of its promoter by E2F3.
Conversely, upregulation of miR-33a followed
increased levels of Dicer in metformin-treated cells.
This might reﬂect a tumor- and stage-speciﬁc issue. We
investigated whether metformin may synergize with
everolimus, a clinical trial-grade mTOR inhibitor. This
conﬁrmed to be true in both breast cancer cell lines and
in the isogenic colon carcinoma cells. Ectopic expres-
sion of CAB39L and SESN1 in everolimus-treated cells
recapitulated the effect of metformin treatment, thus
strengthening the relevance of the two miR-21-5p tar-
gets for the synergistic action of metformin.
Altogether, this may represent a translationally
Figure 3 Calcium-binding protein 39-like (CAB39L) and Sestrin-1 (SESN1) mediated the anticancer effects of metformin through AMP-
activated protein kinase–mammalian target of rapamycin (AMPK-mTOR) signaling. (a, b) Altering the levels of CAB39L and SESN1
mimicked the effect of metformin on the AMPK/mTOR signaling axis. (a) Upper panel. Representative western blotting of whole-cell
lysates from SUM159PT treated with vehicle or metformin or transfected with the expression vectors coding for CAB39L or for two
shRNAs against CAB39L, stained with the indicated pan- and phospho-speciﬁc antibodies. Lower panel. Quantitative densitometry of
phospho-thr172 AMPKα calculated from the analysis of three western blottings including that in panel (a). (b) Upper panel. Representative
western blotting of similarly stained whole-cell lysates from of the same cells treated as from panel (a) and transfected with the expression
vectors for SESN1 or with a siRNA against SESN1. Lower panel. Quantitative densitometry of phospho-thr172 AMPKα calculated from the
analysis of three western blottings including that in panel (b). (c) The LKB1–CAB39L complex was modulated by metformin.
Representative western blotting of whole-cell lysates of vehicle- and metformin-treated SUM159PT cells, immunoprecipitated with anti-
LKB1 and anti-CAB39L antibodies (upper left and lower left panels, respectively). Actin staining was used as a loading control for the
input material (right panel). (d) Metformin stimulates LKB1 kinase activity. Immuno-kinase assay. Histograms showing the enzymatic
activity of LKB1: immunoprecipitates from HEK-293 cells treated or not with 0.5 mM of metformin for 24 h. Mean of two independent
experiments. Statistics (t-test): Po0.001.
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Figure 4 Modulation of calcium-binding protein 39-like (CAB39L) and Sestrin-1 (SESN1) underlies metformin anticancer
activities. (a–c) Colony-forming assay. Histograms showing average colony counts of SUM159PT (a), BT-474 (b) and MCF-7 (c)
cells expressing either a control vector or a CAB39L-expressing vector or CAB39L- or SESN1-targeting shRNAs and treated with
vehicle or metformin (0.5 mM) before seeding at clonal density. Statistics (t-test): Po0.05. (d) Wound healing assay. Percentage
of wound closure (over vehicle) of SUM159PT cells transfected and treated as from panel (a–c), for 48 h. Statistics (t-test):
Po0.05. (e, f) Invasion assay. BT-474 (e) and MCF-7 (f) cells were treated with vehicle or metformin (0.5 mM) for 24 h and the
number of migrated cells was scored. (g, h) Colony-forming assay (g) and invasion assay (h). Histograms showing average
colony counts (g) or the number of migrated cells (h) of SUM159PT cells transfected either with a control vector or CAB39L- or
SESN1-targeting shRNAs and treated with vehicle or metformin (0.5 mM). Histograms indicating the average± s.e. of triplicate
experiments. Statistics (t-test): Po0.05. *Signiﬁcant versus vehicle, ºSigniﬁcant versus untransfected, metformin-treated ones.
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Figure 5 Metformin effects were not inﬂuenced by the status of phosphatase and tensin homolog (PTEN). (a) Colony-forming
assay. Histograms showing average colony counts of BT-549 cells expressing either a control vector or a calcium-binding protein
39-like (CAB39L)-expressing vector or CAB39L- or Sestrin-1 (SESN1)-targeting shRNAs or and treated with vehicle or metformin
(0.5 mM) before seeding at clonal density. Statistics (t-test): Po0.05. (b) Invasion assay. BT-549 cells transfected and treated as
from panel (a) for 24 h and the number of migrated cells was scored. Statistics (t-test): Po0.05. (c, d) Clonogenic assay. Isogenic
HCT116 bearing a wt PTEN (c) or a shRNA targeting PTEN (PTEN K/D) (d) were treated with vehicle or metformin (0.5 mM) and
colonies stained and counted 8 days later. Histograms indicating the average± s.e. Statistics (t-test): Po0.05. (e, f) Invasion
assay. The cells were treated with vehicle or metformin (0.5 mM) for 24 h and the percentage of migrated cells was scored.
Histograms indicating the average± s.e. of triplicate experiments. Statistics (t-test): Po0.05.
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relevant observation that may be worth testing in
clinically relevant models. The latter will be a future
avenue of investigation together with the possibility
that the levels of miR-21-5p and those of CAB39L and
SESN1 may inform selection of patients for combina-
torial therapies.
Claudio Pulito et al.
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Materials and Methods
Cell cultures and treatments
SUM159PT, MCF-7, BT-474 and BT-549 (ATCC,
Manassas, VA, USA) were grown in Dulbecco’s modiﬁed
Eagle’s medium (GIBCO, Thermo Fisher Scieniﬁc, Waltham,
MA, USA) supplemented with 10% non-heat-inactivated fetal
bovine serum (FBS; GIBCO) and 100 Units ml− 1 Penicillin and
100 μg ml− 1 Streptomycin (GIBCO). HCT116 PTEN wt and
PTEN k/o cell lines (Horizon Discovery, Cambridge, UK) were
grown in RPMI supplemented with 5% inactivated FBS
(GIBCO) and 100 Units ml− 1 Penicillin and 100 μg ml− 1
Streptomycin (GIBCO). Metformin (1,1-dimethylbiguanide-
hydrochloride) and everolimus (RAD001) were purchased
from Sigma-Aldrich (St Louis, MO, USA) and SelleckChem
(Houston, TX, USA), respectively.
Chromatin immunoprecipitation
Precleared chromatin was incubated overnight with the
following antibodies: anti-E2F3 (Santa Cruz Biotechnology
#251, Dallas, TX, USA) and anti-Histone H4 (Upstate
#06–866, EMD Millipore, Billerica, MA, USA). All the chro-
matin immunoprecipitation antibodies were used at 4 μg ml− 1 of
diluted chromatin. qPCR was used to assess for DNA enrich-
ment. Primer sequences used for the three different E2F-binding
sites contained in hsa-miR-21-5p promoter are: ﬁrst site Fw:
5′-GCCCCAAGCTACCGTTTTTAA-3′, Rv: 5′-CCGGTTT
GGCAACTGTAGCTA-3′; second site Fw: 5′-GCCTTT
TGAGTCCAGGTGGTAA-3′, Rv: 5′-AGAAAAAGACAC
ATTTGGGAAGAAA-3′; and third site Fw: 5′-GACTTA
CTGAGGTGACTTGAATATCTCC-3′, Rv: 5′-TTCAGCTA
TGGTAAGAGCCTTGG-3′.
RNA processing and qPCR
Total RNA from breast cancer cell lines or tumor engrafment
was extracted by TRI Reagent lysis reagent (Ambion, Thermo
Fisher Scientiﬁc, Waltham, MA, USA), according to the
manufacturer’s instructions. qPCR quantiﬁcation of miRNA
expression was performed using TaqMan MicroRNA Assays
(Applied Biosystems, Thermo Fisher Scientiﬁc, Waltham, MA,
USA) according to the manufacturer’s protocol. The ﬁrst-strand
cDNA was synthesized according to the manufacturer’s
instructions (M-MLV RT Kit, Invitrogen, Thermo Fisher
Scientiﬁc, Waltham, MA, USA). qPCR assays were performed
by STEPOne PCR using the FastStart SYBR Green Master
Mix (Applied Biosystems). Sequences of qPCR primers are
ACTIN Fw: 5′-GGCATGGGTCAGAAGGATT-3′, Rv:
5′-CACACGCAGCTCATTGTAGAAGC-3′; pri-miR-21 Fw:
5′-TTTTGTTTTGCTTGGGAGGA-3′, Rv: 5′-AGCAGAC
AGTCAGGCAGGAT-3′; pre-miR-21 Fw: 5′-CATTGTGGG
TTTTGAAAAGGTTA-3′, Rv: 5′-CCACGACTAGAGGCT
GACTTAGA-3′; CAB39L Fw: 5′-TTAGTGCTCATCC
TCATATCCTGTTTA-3′, Rv: 5′-CCCACAACGTAAGGCA
ATCTG-3′; and SESN1 Fw: 5′-ACTACATTGGAAT
AATGGCTGCGG-3′, Rv: 5′-CCCCAACCAACATGAGGA
AATCAT-3′. RNU49 was used as an endogenous control
to standardize miRNA expression. Taqman probes for the
following miRNA was purchased: hsa-miR-21-5p (Applied
Biosystems).
Human serum specimen
Sera stored at − 80 °C (n = 96) were previously collected
from de-identiﬁed patients with breast cancer enrolled in a
randomized controlled trial to test the effect of different doses of
metformin[38].
Serum RNA extraction and qPCR
Total RNA from serum specimen was extracted by the miR-
Neasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA),
according to the manufacturer’s instructions. The ﬁrst-strand
cDNA was synthesized according to the manufacturer’s
instructions (miScript Reverse Transcription Kit, Qiagen). qPCR
assays were performed by STEPOne PCR (Agilent Technologies,
Santa Clara, CA, USA) using the miScript SYBR Green PCR
Figure 6Metformin synergized with everolimus. (a) Graphs indicating the change in impedance of SUM159PTcells pretreated or not with
metformin (0.5 mM) for 24 h and subsequently treated with everolimus (10–100 nM) for 0–550 min to evaluate early changes in cell ﬁtness.
Statistics (t-test): Po0.05 (versus control). (b) Combination index (CI) versus the fractional effect obtained from SUM159PT cells treated
simultaneously with metformin (0.5 mM) and everolimus (0-100 nM) for 72 h. (c) Histograms showing the average percentage of colonies
formed by SUM159PT cells pretreated with vehicle or metformin (0.5 mM) and subsequently treated with everolimus (0–100 nM). Bars
indicate the average± s.e. of triplicate experiments. Statistics (t-test): Po0.05. (d) Everolimus and metformin treatment synergistically
affected mammalian target of rapamycin (mTOR) signaling. Representative western blotting (upper panel) and quantitative densitometry
(lower panel) phospho-ser2448-mTOR, (phospho-ser235/236)-S6, (phospho-thr37/46)-4-EBP1 and (phospho-thr389)-p70 S6 normalized to their
respective non-phosphorylated protein levels. Bars indicate the average of three independent experiments. Statistics (t-test): Po0.05.
(e) Altering the levels of calcium-binding protein 39-like (CAB39L) and Sestrin-1 (SESN1) affected the response to everolimus. Graphs
indicating the change in impedance of SUM159PT treated as indicated. (f) Metformin affected the clonogenic ability and potentiated the
antitumorigenic effects of everolimus in both phosphatase and tensin homolog (PTEN) wt and PTEN K/D isogenic HCT116 cells. Brieﬂy,
HCT116 cells harboring either PTEN wt (left panel) or deleted for PTEN (right panel) were treated, 24 h after seeding, with metformin, in
the presence or absence of everolimus. Histograms showing the average of three independent clonogenic assays. Colonies were
stained after 9 days. Statistics (t-test): Po0.05. Please note that very similar results were obtained after altering the levels of the miR-21-
5p, whose downregulation strictly mimicked the effect of metformin on the everolimus-treated cells (Supplementary Figure S5).
(g) Invasion assay. HCT116 cells harboring either PTENwt (left panel) or deleted for PTEN (right panel) were treated as from panel (e) for
24 h and the number of migrated cells was scored. Statistics (t-test): Po0.05.
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Kit (Qiagen). miScript primer Assay probe for the following
miRNA was used: hsa-miR-21-5p. The C. Elegans miR-39
(miRNeasy Serum/Plasma Spike-In Control, Qiagen) was used
as control to standardize the miRNA expression.
Clonogenic assays
Cells were grown at 70% conﬂuence and were exposed or not
to a short pulse of metformin (0.5 mM). Subsequently, cells were
detached and seeded at 600 cells per six-well into six-well dishes
(Corning-Costar, New York, NY, USA) in drug-free media.
Fresh media (25%) was added every 3 days. Number of colonies
was scored by Cristal Violet staining 10 days later.
Transwell invasion assay
Migration assay was performed using a 24-well Boyden
chamber with a non-coated 8-mm pore size ﬁlter in the insert
chamber (BD Falcon, Corning-Costar, New York, NY, USA).
Cells were suspended in 0.5 ml Dulbecco’s modiﬁed Eagle’s
medium/F12 media without containing FBS and seeded into the
insert chamber. Cells were allowed to migrate for 24 h into the
bottom chamber containing 0.5 ml of Dulbecco’s modiﬁed
Eagle’s medium/F12 media containing 10% FBS in a humidiﬁed
incubator at 37 °C in 5% CO2. Migrated cells were visualized by
staining with 4,6-diamidino-2-phenylindole and counted. The
average number of cells per ﬁeld was expressed as the percentage
of the control after normalizing for cell number.
Wound-healing migration assay
SUM159PT cells were grown to 80% of conﬂuence in six-well
tissue culture plates and wounded with a sterile 10-μl pipette
tip to remove cells. Phosphate-buffered saline washing was used
to remove loosely attached cells. The progression of migration
was photographed at different times under a light microscope.
The number of cells migrated into the scratched area was
calculated.
Western blotting analysis
Cell lysis was performed on ice for 30 min in NP40 lysis
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM
EGTA, 1 mM EDTA) supplemented with protease and
phosphatase inhibitors (5 mM PMSF, 3 mM NaF, 1 mM DTT,
1 mM NaVO4). Equal amounts of total proteins extracts (30 μg)
were resolved by 8% denaturing sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred for 2 h to
polyvinylidene diﬂuoride membrane. Membranes were blocked
in 5% milk-TBS-0.05% Tween 20 for 1 h and incubated
overnight with the speciﬁc primary antibodies. In the
coimmunoprecipitation, the lysis buffer was modiﬁed
accordingly the protein isoelectric point. Protein concentrations
were determined by colorimetric assay (Bio-Rad, Hercules, CA,
USA). For each immunoprecipitation, 1 μg of rabbit LKB1
(Abcam, Cambridge, UK, ab58786) or mouse CAB39L
antibody (Abcam, ab57880) and 1 μg of rabbit or mouse IgG
(Santa Cruz Biotechnology) as control were used. Precleared
extracts were incubated with protein A/G-Agarose beads
(Thermo Fisher Scientiﬁc, Rockford, IL, USA) in lysis buffer
containing 0.05% bovine serum albumin and antibodies under
constant shaking at 4 °C for 3 h. After incubation, agarose bead-
bound immunocomplexes were rinsed with lysis buffer and
eluted in 50 ml of sodium dodecyl sulfate sample buffer for
western blotting. The following primary antibodies were used:
anti phospho-AMPKα (Thr-172) (Cell Signaling, (Danvers,
MA, USA) #2531); anti-AMPK (Cell Signaling, #9158);
anti-phospho-mTOR (Ser-2448) (Cell Signaling, #2971);
anti-β-Actin (Santa Cruz, sc-81178); anti CAB39L (Abcam,
ab57880); anti SESN1 (Abcam, ab67156); anti LKB1 (Abcam,
ab58786); anti IgG (Santa Cruz, sc-2030); anti-phospho p70 S6
Kinase (thr389) (Cell Signaling, #9234); anti-phospho 4-EBP1
(thr37/46) (Cell Signaling, #2855); and anti-phospho S6
(ser235/236) (Cell Signaling, #2211). All the indicated anti-
bodies were used at the minimum dilutions suggested by the
manufacturer. Secondary horseradish peroxidase-conjugated
was purchased from Santa Cruz. ECL reagent (Amersham,
GE Healthcare, Piscataway, NJ, USA) was employed for the
chemo-luminescence detection. The Uvitec Alliance software
(Eppendorf, Hamburg, Germany) was used to quantify the
obtained data.
Immunoprecipitation and LKB1 kinase activity
HEK-293 cells transfected with an LKB1 expression vector
were treated or not with metformin for 24 h. Cells were lysed at
4 °C in Buffer A (Tris HCl pH 8 50 mM, EGTA 1 mM, EDTA
1 mM, NaF 50 mM, glicerolo 10%, KCl 5 mM, NaCl 170 mM,
DTT 1 mM, protease inhibitor) plus 1% Triton X100. An equal
volume of Buffer B (Tris HCl pH 8 50 mM, NaF 50 mM,
glicerolo 7%, KCl 5 mM,MgCl2 0.2 mM, CaCl2 0.2 mM, protease
inhibitor) was added after 20 min. Three milligrams of
precleared cell lysate protein was incubated at 4 °C overnight
with human LKB1 antibody.
The immune-precipitates were washed four times with Buffer
B plus 0.15% NP40 and NaCl 100 mM. LKB1 activity was
Table 2 CC50 values
CC50 (nM)
Vehicle 16.47± 0.5
Metformin 7.88113± 0.36
21 inhibitor 6.93223± 0.49
Mimic 21 42.2588± 0.47
Si SESN1 58.6414± 0.36
Over SESN1 12.7958± 0.38
Sh CAB39L 54.8008± 0.3
Over CAB39L 12.7175± 0.42
Sh CAB39L si SESN 1 81.3338± 0.45
Sh CAB39L over SESN 1 11.0902± 0.4
Sh CAB39L over CAB39L 8.68656± 0.3
OverCAB39L over SESN1 3.30453± 0.29
Abbreviations: CAB39L, calcium-binding protein 39-like; CC50, 50%
cytotoxic concentration; SESN1, Sestrin-1. Altering the levels of CAB39L
and/or SESN1 affected everolimus response. Here are reported the CC50
values obtained from viability assay experiments conducted in
SUM159PT cells treated with everolimus (0.001–100 nM) for 72 h.
CompuSyn software (http://www.combosyn.com/feature.html) was used
for analysis.
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measured in a total volume of 50 μl consisting of 50 mMTris HCl
pH 7.5, 0.1 mM EGTA, 0.5 mM DTT, 10 mM MgCl2, 0.1 mM
ATP and 200 uM of LKB1 substrate peptide[53] (Jena
Bioscience, Jena, Germany, #PE-215). LKB1 phospho-
transferase activity was assessed by using the ADP-Glo Kinase
Assay (Promega, Madison, WI, USA, #V6930), according to
the manufacturer’s instructions.
EnSpire cellular label-free platform
SUM159PT, BT-549 and MCF-7 cells were seeded in
specially designed 384-well plate with highly precise optical
sensors able to measure changes in light refraction resulting
from dynamic mass redistribution within the cell’s monolayer.
Change in the light refraction was indicated by a shift in
wavelength.
Luciferase assays
For the 3′-UTR reporter assays, cells were co-transfected in 24-
well plates PSICHECK2-CAB39L/or SESN1-3′UTR or PSI-
CHECK2 (as a control) together with different doses of
hsa-miR-21 mimic or control (Ambion, Thermo Scientiﬁc,
Waltham, MA, USA). For the miR-21-5p promoter activity, the
pMLuc-1 AccepTor plasmid (Novagen, Madison, WI, USA) was
used for the generation of miR-21-5p promoter reporter constructs
[21]. Renilla luciferase activities were measured 48 h after trans-
fection using the Dual Luciferase Reporter Assay System (Pro-
mega) in the GloMax 96 Microplate Luminometer (Promega).
Fireﬂy luciferase was used to normalize the Renilla luciferase.
Plasmid and transfection
The full-length 3′-UTR of the human CAB39L and
SESN1 genes (OriGene, Rockville, MD, USA) were
ampliﬁed and inserted downstream of the Renilla luciferase
gene into the Not I site of the dual luciferase reporter
plasmid psiCHECK-2 (Promega). CAB39L, SESN1 and
miR-21-promoter mutants were made with the
QuikChange site-directed mutagenesis Kit (Stratagene,
San Diego, CA, USA) using the following primers: CAB39L
Fw: 5′-GTGATGGGCAATTATAGAATGACGATTTAT
TAGAAAAAAATTGCTTTTATCAACATCTGATACAAT
GGCT-3′, Rv: 5′-AGCCATTGTATCAGATGTTGATA
AAAGCAATTTTTTTCTAATAAATCGTCATTCTATAA
TTGCCCATCAC-3′; SESN1 Fw: 5′-GTAGTCGTAAATT
TTTTTCGTTAAATCTAATCGGTTTTAATTCACGGATT
TTCGTTAAATCTAA-3′, Rv: 5′-TTTTCGTTAAATCTAAT
TTTTTCGTACGTTTAAAAAATCTAATTTTTTCGTACG
TTTACGGCTTT-3′; and miR-21-promoter Fw: 5′-CTTCT
CCCCTCTGGGAAGTGAAATTACATTCACAGC-3′, Rv:
5′-GCTGTGAATGTAATTTCACTTCCCAGAGGGGAGA
AG-3′. Transfections were performed with Lipofectamine 2000
or Lipofectamine RNAiMax (Life Technologies) according to
the manufacturer’s recommendations, using either negative
control (NC) (Life Technologies) or mimic-21-5p (Life
Technologies) or miR-21-5p inhibitor (Life Technologies).
SESN1 and E2F3 were silenced in SUM159PT cell line using
siRNAs: siSESN1 5′-GGCATTAGAATTCCTCGA(dTdT)-3′
(Euroﬁns MWG, Louisville, KY, USA) and siE2F3 (1),
5′-CGUCCAAUGGAUGGGCUGC-3′[54] (Euroﬁns MWG),
siE2F3 (2) 5′-UAACCUUUGAUUCUCUGAAUCCUCG-3′
[55] (Euroﬁns MWG), respectively. siScr 5′-AAUUCAGC
GUGUCCGGGGAG(dTdT)-3′ (Euroﬁns MWG) was used as
a control while CAB39L was stably silenced in SUM159PT
using shRNA expression vector (OriGene, TR314249).
SUM159PT differently expressing high levels of CAB39L or
Figure 7 Working model. Metformin treatment downregulated, transcriptionally, the levels of miR-21-5p by inhibiting its
transcription through increased occupancy of the promoter regions by E2F3. Consequently, this relieved the mir-21-5p-mediated
repression of calcium-binding protein 39-like (CAB39L) and Sestrin-1 levels. This, in turn, activated AMP-activated protein kinase
(AMPK) and inhibited mammalian target of rapamycin (mTOR) signaling, discouraging clonogenicity and invasion of the treated
cells, independently of their phosphatase and tensin homolog (PTEN) status.
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SESN1 were obtained with a speciﬁc plasmid containing either
CAB39L (OriGene, SC320905) or SESN1 (OriGene, SC212558)
coding sequence. HEK293 cells expressing different
levels of E2F3 were obtained by using a pCMV-Neo-Bam
E2F3a[56]. It was a gift from Jacqueline Lees (Addgene plas-
mid # 37970, Cambridge, MA, USA).
RNA-Seq
Total RNA from metformin- or vehicle-treated
SUM159PT cells was isolated using miRNeasy including the
optional DNase treatment (Qiagen). RNA quality was veriﬁed
using an Agilent Bioanalyzer (Agilent Technologies; RNA 6000
Nano Kit). All RNAs used for subsequent library preparation
had an RNA integrity number 49.0. RNA libraries for
sequencing were generated according to the Epicenter ScriptSeq
v2 RNA-Seq Library Preparation Kit (Illumina, Madison, WI,
USA) with an initial ribosomal depletion step using Ribo-Zero
Magnetic Gold (Illumina, Madison, WI, USA). Starting
material was 5 μg of total RNA. Based on qPCR quantiﬁcation,
libraries were normalized to 1 nM and denatured by using 0.1 N
NaOH. Cluster ampliﬁcation of denatured templates was
carried out according to the manufacturer’s protocol (Illumina,
Inc., San Diego, CA, USA). Sequencing was performed on a
Genome Analyzer IIx (Illumina) in paired-end mode; quality
control has been performed to assess sequence data quality and
to discard low quality reads. For the analysis, we exploited the
RNA-Seq analysis workﬂow RAP that comprises of read
mapping, transcript assembly and abundancy estimation
followed by transcript-based differential expression via the
Tuxedo suite. Paired-end reads were mapped to the human
genome assembly hg19 with TopHat and further analyzed by the
Cufﬂinks-Cuffdiff pipeline to identify differentially expressed
transcripts. We run the pipeline without novel transcript
discovery, correcting for multiply mapping reads with the ‘-u’
option of Cuffdiff and a mask ﬁle for rRNAs and tRNAs. The
RNA-Seq was conducted with three biological replicates.
Cell viability assay
Viability of treated cells was assessed using ATPlite assay
(Perkin Elmer, Waltham, MA, USA) accordingly to the
manufacturer’s instructions. Cells (8 × 102 cells) were seeded in
96-well plates and cultured for 24 h and treated for 72 h with
everolimus. Each plate was evaluated immediately on a
microplate reader (Expire Technology, Perkin Elmer, Waltham,
MA, USA).
In silico individuation of miR-21-5p putative targets
Putative miR-21-5p targets were identiﬁed using the
predictive target search of miRWalk with the programs
DIANAmT, miRanda, miRDB, miRWalk, RNA22 and
Targetscan, taking only those genes in consideration that were
predicted to be miR-21-5p targets by at least ﬁve different
programs and resulted as common deregulated in three different
data sets. A permutation test and a false discovery rate
procedure were used to assess a signiﬁcant difference between
tumoral and normal samples. Targets were sorted by a
combined correlation P-value calculated with Stouffer’s and
Fisher’s methods.
Statistical analysis
For miRNA analysis, Pearson’s correlation coefﬁcient was
calculated to assess quality of replicates. Analysis of variance
test (α = 5%) was performed to assess statistical signiﬁcance of
the observed differences in miRNA proﬁling. Generally,
Student’s t-test was used to assess signiﬁcance of the data.
P-valueso0.05 were considered statistically signiﬁcant.
CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA) was
used for CC50 determination.
Immunohistochemical analysis
Formalin-ﬁxed and parafﬁn-embedded 5 μm sections from
mice tumor sections were stained with anti-CAB39L antibody
(Abcam, ab57880). Seven ﬁelds chosen randomly from each
sample were scored.
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